1. Bonilla-Felix M, Parra C, Dajani T, Ferris M, Swinford RD, Portman RJ, Verani R. Changing patterns in the histopathology of idiopathic NS in children.
Kidney Int 55:1999;1885–1890.
2. Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–1979 and 1995–1997.
Am J Kidney Dis 30:1997;621–631.
3. Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte.
Physiol Rev 83:2003;253–307.
4. Tryggvason K, Wartiovaara J. Molecular basis of glomerular permselectivity.
Curr Opin Nephrol Hypertens 10:2001;543–549.
5. Asanuma K, Kim K, Oh J, Giardino L, Chabanis S, Faul C, Reiser J, Mundel P. Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner.
J Clin Invest 115:2005;1188–1198.
6. Kistler AD, Peev V, Forst AL, El Hindi S, Altintas MM, Reiser J. Enzymatic disease of the podocyte.
Pediatr Nephrol 25:2010;1017–1023.
7. Meyrier A. Treatment of primary focal segmental glomerulosclerosis.
Nephrol Dial Transplant 14:1999;74–78.
8. Oh J, Kemper MJ. Second-line options for refractory steroid-sensitive and -resistant nephrotic syndrome.
Expert Rev Clin Pharmacol 3:2010;527–537.
9. Mathieson PW. The podocyte as a target for therapies—new and old.
Nat Rev Nephrol 8:2012;52–56.
10. Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function.
Lancet 2:1974;556–560.
11. Audard V, Larousserie F, Grimbert P, Abtahi M, Sotto JJ, Delmer A, Boue F, Nochy D, Brousse N, Delarue R, Remy P, Ronco P, Sahali D, Lang P, Hermine O. Minimal change nephrotic syndrome and classical Hodgkin׳s lymphoma: report of 21 cases and review of the literature.
Kidney Int 69:2006;2251–2260.
12. Abdel-Hafez M, Shimada M, Lee PY, Johnson RJ, Garin EH. Idiopathic nephrotic syndrome and atopy: is there a common link?
Am J Kidney Dis 54:2009;945–953.
13. Frank C, Herrmann M, Fernandez S, Dirnecker D, Böswald M, Kolowos W, Ruder H, Haas JP. Dominant T cells in idiopathic nephrotic syndrome of childhood.
Kidney Int 57:2000;510–517.
14. Neuhaus TJ, Wadhwa M, Callard R, Barratt TM. Increased IL-2, IL-4 and interferon-gamma (IFN-gamma) in steroid-sensitive nephrotic syndrome.
Clin Exp Immunol 100:1995;475–479.
15. van den Berg JG, Weening JJ. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome.
Clin Sci (Lond) 107:2004;125–136.
16. Ponticelli C, Glassock RJ.. Glomerular diseases: membranous nephropathy—a modern view.
Clin J Am Soc Nephrol 9:2014;609–616.
17. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, Rosenberg PB. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis.
Science 308:2005;1801–1804.
18. Ambalavanan S, Fauvel JP, Sibley RK, Myers BD. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy.
J Am Soc Nephrol 7:1996;290–298.
19. Callís L, Vila A, Nieto J, Fortuny G. Effect of cyclosporin A on proteinuria in patients with Alport׳s syndrome.
Pediatr Nephrol 6:1992;140–144.
20. Chen D, Jefferson B, Harvey SJ, Zheng K, Gartley CJ, Jacobs RM, Thorner PS. Cyclosporine A slows the progressive renal disease of Alport syndrome (X-linked hereditary nephritis): results from a canine model.
J Am Soc Nephrol 14:2003;690–698.
21. Malina M, Cinek O, Janda J, Seeman T. Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation.
Pediatr Nephrol 24:2009;2051–2053.
22. Savin VJ, McCarthy ET, Sharma M. Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis.
Kidney Res Clin Pract 31:2012;205–213.
23. Wada T, Pippin JW, Marshall CB, Griffin SV, Shankland SJ. Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins.
J Am Soc Nephrol 16:2005;2615–2625.
24. Wada T, Pippin JW, Nangaku M, Shankland SJ. Dexamethasone’s prosurvival benefits in podocytes require extracellular signal-regulated kinase phosphorylation.
Nephron Exp Nephrol 109:2008;e8–e19.
25. Xing CY, Saleem MA, Coward RJ, Ni L, Witherden IR, Mathieson PW. Direct effects of dexamethasone on human podocytes.
Kidney Int 70:2006;1038–1045.
26. Ransom RF, Lam NG, Hallett MA, Atkinson SJ, Smoyer WE. Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization.
Kidney Int 68:2005;2473–2483.
27. Mutch RS, Hutson PR. Levamisole in the adjuvant treatment of colon cancer.
Clin Pharm 10:1991;95–109.
28. Sajid MS, Iqbal Z, Muhammad G, Iqbal MU. Immunomodulatory effect of various anti-parasitics: a review.
Parasitology 132:2006;301–313.
29. Szeto C, Gillespie KM, Mathieson PW. Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance.
Immunology 100:2000;217–224.
30. Jiang L, Dasgupta I, Hurcombe JA, Colyer HF, Mathieson PW, Welsh GI. Levamisole in steroid-sensitive nephrotic syndrome: usefulness in adult patients and laboratory insights into mechanisms of action via direct action on the kidney podocyte.
Clin Sci (Lond) 128:2015;883–893.
31. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, Ponticelli C, Saito T, Choukroun G, Nachman P, Praga M, Yoshikawa N. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations.
Kidney Int 72:2007;1429–1447.
32. Meyrier A. Treatment of idiopathic nephrosis by immunophillin modulation.
Nephrol Dial Transplant 18:2003;vi79–vi86.
33. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.
Nat Med 14:2008;931–938.
34. Reiser J, Polu KR, Möller CC, Kenlan P, Altintas MM, Wei C, Faul C, Herbert S, Villegas I, Avila-Casado C, McGee M, Sugimoto H, Brown D, Kalluri R, Mundel P, Smith PL, Clapham DE, Pollak MR. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function.
Nat Genet 37:2005;739–744.
35. Möller CC, Wei C, Altintas MM, Li J, Greka A, Ohse T, Pippin JW, Rastaldi MP, Wawersik S, Schiavi S, Henger A, Kretzler M, Shankland SJ, Reiser J. Induction of TRPC6 channel in acquired forms of proteinuric kidney disease.
J Am Soc Nephrol 18:2007;29–36.
36. Nijenhuis T, Sloan AJ, Hoenderop JG, Flesche J, van Goor H, Kistler AD, Bakker M, Bindels RJ, de Boer RA, Möller CC, Hamming I, Navis G, Wetzels JF, Berden JH, Reiser J, Faul C, van der Vlag J. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway.
Am J Pathol 179:2011;1719–1732.
37. Zietse R, Wenting GJ, Kramer P, Schalekamp MA, Weimar W. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome.
Clin Sci (Lond) 82:1992;641–650.
38. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective.
Immunol Rev 237:2010;264–283.
39. Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor.
Blood 107:2006;1070–1077.
40. Salama AD, Pusey CD. Drug insight: rituximab in renal disease and transplantation.
Nat Clin Pract Nephrol 2:2006;221–230.
41. Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome.
Pediatr Nephrol 20:2005;1660–1663.
42. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment.
N Engl J Med 354:2006;1961–1963.
43. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.
Sci Transl Med 3:2011;85ra46.
44. Yoo TH, Pedigo CE, Guzman J, Correa-Medina M, Wei C, Villarreal R, Mitrofanova A, Leclercq F, Faul C, Li J, Kretzler M, Nelson RG, Lehto M, Forsblom C, Groop PH, Reiser J, Burke GW, Fornoni A, Merscher S. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.
J Am Soc Nephrol 26:2015;133–147.
45. Riella LV, Sayegh MH. T-cell co-stimulatory blockade in transplantation: two steps forward one step back!
Expert Opin Biol Ther 13:2013;1557–1568.
46. Moreland L, Bate G, Kirkpatrick P. Abatacept.
Nat Rev Drug Discov 5:2006;185–186.
47. Chopra B, Sureshkumar KK. Co-stimulatory blockade with belatacept in kidney transplantation.
Expert Opin Biol Ther 14:2014;563–567.
48. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA, Mundel P. Induction of B7-1 in podocytes is associated with nephrotic syndrome.
J Clin Invest 113:2004;1390–1397.
49. Bhat S, Czuczman MS. Galiximab: a review.
Expert Opin Biol Ther 10:2010;451–458.
50. Vinjamaram S, Czuczman MS, Hernandez-Ilizaliturri FJ. The use of galiximab in non-Hodgkin lymphoma.
Clin Lymphoma Myeloma 8:2008;277–282.
51. Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW 3rd, Mundel P. Abatacept in B7-1-positive proteinuric kidney disease.
N Engl J Med 369:2013;2416–2423.
52. Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids—receptor revelations.
Science 294:2001;1875–1878.
53. Goetzl EJ, Liao JJ, Huang MC. Regulation of the roles of sphingosine 1-phosphate and its type 1 G protein-coupled receptor in T cell immunity and autoimmunity.
Biochim Biophys Acta 1781:2008;503–507.
54. O’Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L. FTY720 D2201 Study Group: Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
Neurology 72:2009;73–79.
55. Kappos L, Antel J, Comi G, Montalban X, O׳Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW. FTY720 D2201 Study Group: Oral fingolimod (FTY720) for relapsing multiple sclerosis.
N Engl J Med 355:2006;1124–1140.
56. Awad AS, Ye H, Huang L, Li L, Foss FW Jr, Macdonald TL, Lynch KR, Okusa MD. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney.
Am J Physiol Renal Physiol 290:2006;F1516–F1524.
57. Awad AS, Rouse MD, Khutsishvili K, Huang L, Bolton WK, Lynch KR, Okusa MD. Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes.
Kidney Int 79:2011;1090–1098.
58. Schwecke T, Aparicio JF, Molnár I, König A, Khaw LE, Haydock SF, Oliynyk M, Caffrey P, Cortés J, Lester JB, Böhm GA, Staunton J, Leadlay PF. The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin.
Proc Natl Acad Sci U S A 92:1995;7839–7843.
59. Hay N, Sonenberg N. Upstream and downstream of mTOR.
Genes Dev 18:2004;1926–1945.
60. Fogo AB. The targeted podocyte.
J Clin Invest 121:2011;2142–2145.
61. Dodson M, Darley-Usmar V, Zhang J. Cellular metabolic and autophagic pathways: traffic control by redox signaling.
Free Radic Biol Med 63:2013;207–221.
62. Zhang MZ, Wang Y, Paueksakon P, Harris RC. Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy.
Diabetes 63:2014;2063–2072.
63. Inoki K, Mori H, Wang J, Suzuki T, Hong S, Yoshida S, Blattner SM, Ikenoue T, Rüegg MA, Hall MN, Kwiatkowski DJ, Rastaldi MP, Huber TB, Kretzler M, Holzman LB, Wiggins RC, Guan KL. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice.
J Clin Invest 121:2011;2181–2196.
64. Gödel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, Debreczeni-Mór A, Lindenmeyer MT, Rastaldi MP, Hartleben G, Wiech T, Fornoni A, Nelson RG, Kretzler M, Wanke R, Pavenstädt H, Kerjaschki D, Cohen CD, Hall MN, Rüegg MA, Inoki K, Walz G, Huber TB. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice.
J Clin Invest 121:2011;2197–2209.
65. Diekmann F, Andrés A, Oppenheimer F. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
Transplant Rev (Orlando) 26:2012;27–29.
66. Gong R.. The renaissance of corticotropin therapy in proteinuric nephropathies.
Nat Rev Nephrol 8:2011;122–128.
67. Beck L.H. Jr, Salant D.J.. Membranous nephropathy: from models to man.
J Clin Invest 124:2014;2307–2314.